Journal
ANNUAL REVIEW OF MEDICINE
Volume 61, Issue -, Pages 105-119Publisher
ANNUAL REVIEWS
DOI: 10.1146/annurev.med.60.041807.123500
Keywords
alveolar proteinosis; interstitial lung disease; respiratory distress syndrome; pulmonary fibrosis; pulmonary alveolar microlithiasis
Categories
Funding
- [NHLBI-HL085610]
- [HL061646]
- [HL090156]
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL090156, R01HL085610, P01HL061646] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The alveolar region of the lung creates an extensive epithelial surface that mediates the transfer of oxygen and carbon dioxide required for respiration after birth. Maintenance of pulmonary function depends on the function of type II epithelial cells that synthesize and secrete pulmonary surfactant lipids and proteins, reducing the collapsing forces created at the air-liquid interface in the alveoli. Genetic and acquired disorders associated with the surfactant system cause both acute and chronic lung disease. Mutations in the ABCA3, SFTPA, SFTPB, SPTPC, SCL34A2, and TERT genes disrupt type II cell function and/or surfactant homeostasis, causing neonatal respiratory failure and chronic interstitial lung disease. Defects in GM-CSF receptor function disrupt surfactant clearance, causing pulmonary alveolar proteinosis. Abnormalities in the surfactant system and disruption of type II cell homeostasis underlie the pathogenesis of pulmonary disorders previously considered idiopathic, providing the basis for improved diagnosis and therapies of these rare lung diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available